BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GXV813 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GXV813\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07467993-9513@assetmemo.bio
DTSTAMP:20261121T005644Z
DTSTART;VALUE=DATE:20270729
DTEND;VALUE=DATE:20270730
SUMMARY:GXV813: Phase 2 readout est. (NCT07467993)
DESCRIPTION:GXV813\, phase 2\, Schizophrenia.\nStudy: Study to Assess the S
 afety\, Tolerability\, and Treatment Response of GXV813 in Hospitalized Ad
 ults With Schizophrenia\nEstimated primary completion: 29 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gxv813#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07467993
URL:https://assetmemo.bio/drug/gxv813#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
